Tilt Investment Management Holdings PBC Has $428,000 Holdings in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX)

Tilt Investment Management Holdings PBC lowered its position in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 23.6% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 1,052 shares of the pharmaceutical company’s stock after selling 325 shares during the period. Tilt Investment Management Holdings PBC’s holdings in Vertex Pharmaceuticals were worth $428,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also modified their holdings of VRTX. Venturi Wealth Management LLC grew its holdings in shares of Vertex Pharmaceuticals by 1.1% during the fourth quarter. Venturi Wealth Management LLC now owns 2,293 shares of the pharmaceutical company’s stock worth $933,000 after purchasing an additional 24 shares during the last quarter. Arthur M. Cohen & Associates LLC grew its holdings in Vertex Pharmaceuticals by 3.2% during the 4th quarter. Arthur M. Cohen & Associates LLC now owns 800 shares of the pharmaceutical company’s stock worth $326,000 after acquiring an additional 25 shares during the last quarter. Baystate Wealth Management LLC increased its position in Vertex Pharmaceuticals by 49.0% in the 4th quarter. Baystate Wealth Management LLC now owns 76 shares of the pharmaceutical company’s stock valued at $31,000 after acquiring an additional 25 shares in the last quarter. Cooper Financial Group raised its stake in shares of Vertex Pharmaceuticals by 1.0% in the third quarter. Cooper Financial Group now owns 3,020 shares of the pharmaceutical company’s stock worth $1,050,000 after acquiring an additional 29 shares during the last quarter. Finally, Arjuna Capital lifted its position in shares of Vertex Pharmaceuticals by 0.7% during the third quarter. Arjuna Capital now owns 4,375 shares of the pharmaceutical company’s stock worth $1,521,000 after purchasing an additional 29 shares in the last quarter. 90.96% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In related news, COO Stuart A. Arbuckle sold 4,295 shares of the stock in a transaction that occurred on Monday, February 12th. The stock was sold at an average price of $420.24, for a total transaction of $1,804,930.80. Following the sale, the chief operating officer now owns 75,718 shares of the company’s stock, valued at $31,819,732.32. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. In other news, COO Stuart A. Arbuckle sold 4,295 shares of the company’s stock in a transaction on Monday, February 12th. The stock was sold at an average price of $420.24, for a total transaction of $1,804,930.80. Following the completion of the sale, the chief operating officer now directly owns 75,718 shares in the company, valued at approximately $31,819,732.32. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, EVP Amit Sachdev sold 3,222 shares of the company’s stock in a transaction dated Monday, February 12th. The stock was sold at an average price of $420.24, for a total transaction of $1,354,013.28. Following the sale, the executive vice president now directly owns 74,364 shares of the company’s stock, valued at approximately $31,250,727.36. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 12,381 shares of company stock worth $5,203,249. Corporate insiders own 0.20% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages recently weighed in on VRTX. Cantor Fitzgerald reissued an “overweight” rating and issued a $440.00 price target on shares of Vertex Pharmaceuticals in a report on Tuesday, February 20th. Wells Fargo & Company boosted their target price on Vertex Pharmaceuticals from $500.00 to $540.00 and gave the stock an “overweight” rating in a research report on Tuesday, February 6th. UBS Group cut their price target on Vertex Pharmaceuticals from $498.00 to $466.00 and set a “buy” rating on the stock in a research note on Wednesday. Royal Bank of Canada lifted their price objective on Vertex Pharmaceuticals from $397.00 to $420.00 and gave the stock a “sector perform” rating in a research report on Tuesday, February 6th. Finally, JPMorgan Chase & Co. upped their target price on shares of Vertex Pharmaceuticals from $390.00 to $438.00 and gave the company an “overweight” rating in a research report on Thursday, February 1st. Three research analysts have rated the stock with a sell rating, six have issued a hold rating, fourteen have given a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $429.45.

Vertex Pharmaceuticals Stock Performance

NASDAQ VRTX traded up $2.46 on Thursday, reaching $395.56. The stock had a trading volume of 532,739 shares, compared to its average volume of 1,239,377. The company has a debt-to-equity ratio of 0.02, a current ratio of 3.99 and a quick ratio of 3.78. The company has a market cap of $102.24 billion, a P/E ratio of 28.30, a price-to-earnings-growth ratio of 1.84 and a beta of 0.35. The firm has a fifty day moving average of $414.76 and a two-hundred day moving average of $396.76. Vertex Pharmaceuticals Incorporated has a 1-year low of $316.43 and a 1-year high of $448.40.

Vertex Pharmaceuticals (NASDAQ:VRTX) last released its quarterly earnings results on Monday, February 5th. The pharmaceutical company reported $4.20 EPS for the quarter, beating the consensus estimate of $3.85 by $0.35. Vertex Pharmaceuticals had a net margin of 36.68% and a return on equity of 21.91%. The business had revenue of $2.52 billion for the quarter, compared to the consensus estimate of $2.50 billion. During the same period in the prior year, the company posted $3.33 earnings per share. On average, equities research analysts anticipate that Vertex Pharmaceuticals Incorporated will post 15.08 EPS for the current year.

About Vertex Pharmaceuticals

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.